eTheRNA immunotherapies, a clinical-stage company and VUB spin-off developing mRNA-based immunotherapies with in-house GMP certified production and process development capabilities, and Quantoom Biosciences announced that they will collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material.
Quantoom and eTheRNA will work together to build an advanced, small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need.
Quantoom Biosciences is a Belgian biotech company aiming to improve access to essential medicines through innovative bioproduction methods.